Tedla Yacob G, Driver Steven, Szklo Moyses, Kuller Lewis, Lima Joao Ac, Michos Erin D, Ning Hongyan, deFilippi Christopher R, Greenland Philip
Vanderbilt University Medical Center, Department of Medicine, Division of Epidemiology, Nashville, TN, United States.
Advocate Aurora Health, Advocate Heart Institute, Chicago, IL, United States.
Am J Prev Cardiol. 2023 Feb 11;13:100471. doi: 10.1016/j.ajpc.2023.100471. eCollection 2023 Mar.
Elevated highly-sensitive cardiac troponin-T (hs-cTnT≥14 ng/L) and low ankle-brachial index (ABI<0.9) are risk factors for atherosclerotic cardiovascular diseases (ASCVD) but their joint effect on the risk of ASCVD events is unknown.
We used data from the two population-based cohort studies, the Multi-Ethnic study of Atherosclerosis (MESA) and Cardiovascular Heart Study (CHS) among 10,897 participants free of CVD events at baseline (mean age 66.3 years, 44.7% males). Incident ASCVD was defined as CHD (fatal/non-fatal MI or revascularization), transient ischemic attack, or stroke,. Hazard ratio (HR) and 95% CI was calculated from a Cox regression model. Interaction on the additive scale was assessed using relative excess risk due to interaction (RERI) and interaction on the multiplicative scale was assessed by Likelihood ratio (LR) test.
At baseline (2000-2002 for MESA and 1989-1990 for CHS), 10.2% of participants had elevated hs-cTnT and 7.5% had low ABI. During a median follow-up of 13.6 years (interquartile range, 7.5-14.7 years), there were 2590 incident ASCVD and 1542 incident CHD events. The hazard of CHD and ASCVD was higher in participants with both elevated hs-cTnT and low ABI [HR(95% CI): CHD: 2.04 (1.45, 2.88), ASCVD: 2.05 (1.58, 2.66)] than those with only elevated hs-cTnT [CHD: 1.65 (1.37, 1.99), ASCVD: 1.67 (1.44, 1.99)] or only low ABI [CHD: 1.87 (1.52, 2.31), ASCVD: 1.67 (1.42, 1.97)]. Antagonistic multiplicative interaction was observed for CHD (LR test -value=0.042) but not for ASCVD (LR test -value =0.08). No significant additive interaction was detected for CHD and ASCVD (RERI -value ≥0.23).
The observed joint effect of elevated cTnT and low ABI on ASCVD risk was smaller (i.e., antagonistic interaction) than that expected by the combined independent effects of each risk factor.
高敏心肌肌钙蛋白T升高(hs-cTnT≥14 ng/L)和踝臂指数降低(ABI<0.9)是动脉粥样硬化性心血管疾病(ASCVD)的危险因素,但它们对ASCVD事件风险的联合作用尚不清楚。
我们使用了两项基于人群的队列研究的数据,即动脉粥样硬化多族裔研究(MESA)和心血管健康研究(CHS),共有10897名基线时无CVD事件的参与者(平均年龄66.3岁,男性占44.7%)。新发ASCVD定义为冠心病(致命性/非致命性心肌梗死或血运重建)、短暂性脑缺血发作或中风。通过Cox回归模型计算风险比(HR)和95%置信区间。使用交互作用相对超额风险(RERI)评估相加尺度上的交互作用,通过似然比(LR)检验评估相乘尺度上的交互作用。
在基线时(MESA为2000 - 2002年,CHS为1989 - 1990年),10.2%的参与者hs-cTnT升高,7.5%的参与者ABI降低。在中位随访13.6年(四分位间距为7.5 - 14.7年)期间,有2590例新发ASCVD事件和1542例新发冠心病事件。hs-cTnT升高且ABI降低的参与者发生冠心病和ASCVD的风险高于仅hs-cTnT升高的参与者[HR(95% CI):冠心病:2.04(1.45, 2.88),ASCVD:2.05(1.58, 2.66)]或仅ABI降低的参与者[冠心病:1.87(1.52, 2.31),ASCVD:1.67(1.42, 1.97)]。观察到冠心病存在拮抗相乘交互作用(LR检验P值 = 0.042),但ASCVD不存在(LR检验P值 = 0.08)。未检测到冠心病和ASCVD有显著的相加交互作用(RERI P值≥0.23)。
观察到的cTnT升高和ABI降低对ASCVD风险的联合作用小于每个危险因素独立作用之和所预期的联合作用(即拮抗交互作用)。